Algernon Pharmaceuticals Inc. (AGNPF)
USD 0.05
(3.65%)
USD 0.05
(3.65%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -6.78 Million CAD | -12.01% |
| 2022 | -6.05 Million CAD | 21.72% |
| 2021 | -7.73 Million CAD | 9.42% |
| 2020 | -8.53 Million CAD | -350.43% |
| 2019 | -1.89 Million CAD | -102.17% |
| 2018 | -937.59 Thousand CAD | 50.41% |
| 2017 | -1.89 Million CAD | 72.51% |
| 2016 | -6.87 Million CAD | -842.17% |
| 2015 | -729.89 Thousand CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -1 Million CAD | -92.48% |
| 2024 Q3 | 1.44 Million CAD | 243.83% |
| 2024 Q1 | -521.55 Thousand CAD | 79.36% |
| 2023 Q1 | -1.88 Million CAD | 15.21% |
| 2023 Q4 | -2.52 Million CAD | -124.11% |
| 2023 FY | -6.78 Million CAD | -12.01% |
| 2023 Q3 | -1.12 Million CAD | 9.63% |
| 2023 Q2 | -1.24 Million CAD | 33.65% |
| 2022 Q1 | -1.2 Million CAD | -399.68% |
| 2022 Q4 | -2.21 Million CAD | -176.93% |
| 2022 Q3 | -800.61 Thousand CAD | 56.39% |
| 2022 Q2 | -1.83 Million CAD | -52.93% |
| 2022 FY | -6.05 Million CAD | 21.72% |
| 2021 Q4 | -240.26 Thousand CAD | 85.65% |
| 2021 Q3 | -1.67 Million CAD | 29.82% |
| 2021 FY | -7.73 Million CAD | 9.42% |
| 2021 Q2 | -2.38 Million CAD | 30.55% |
| 2021 Q1 | -3.43 Million CAD | -14.95% |
| 2020 Q2 | -787.4 Thousand CAD | -373.38% |
| 2020 FY | -8.53 Million CAD | -350.43% |
| 2020 Q3 | -4.59 Million CAD | -483.44% |
| 2020 Q4 | -2.98 Million CAD | 34.97% |
| 2020 Q1 | -166.33 Thousand CAD | 60.87% |
| 2019 Q4 | -425.06 Thousand CAD | 20.09% |
| 2019 Q2 | -444.81 Thousand CAD | 9.92% |
| 2019 Q1 | -493.77 Thousand CAD | -158.16% |
| 2019 FY | -1.89 Million CAD | -102.17% |
| 2019 Q3 | -531.91 Thousand CAD | -19.58% |
| 2018 Q1 | -193.3 Thousand CAD | 33.77% |
| 2018 FY | -937.59 Thousand CAD | 50.41% |
| 2018 Q4 | -191.26 Thousand CAD | 51.59% |
| 2018 Q3 | -395.08 Thousand CAD | -150.15% |
| 2018 Q2 | -157.93 Thousand CAD | 18.3% |
| 2017 Q3 | -767.19 Thousand CAD | -136.35% |
| 2017 FY | -1.89 Million CAD | 72.51% |
| 2017 Q4 | -291.88 Thousand CAD | 61.95% |
| 2017 Q1 | -506.92 Thousand CAD | -83.49% |
| 2017 Q2 | -324.59 Thousand CAD | 35.97% |
| 2016 Q1 | -4.1 Million CAD | -681.12% |
| 2016 Q4 | -276.26 Thousand CAD | 40.91% |
| 2016 Q3 | -467.55 Thousand CAD | 76.89% |
| 2016 Q2 | -2.02 Million CAD | 50.78% |
| 2016 FY | -6.87 Million CAD | -842.17% |
| 2015 Q3 | -203.73 Thousand CAD | 0.0% |
| 2015 Q4 | -526.15 Thousand CAD | -158.25% |
| 2015 FY | -729.89 Thousand CAD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Bioxytran, Inc. | -4.28 Million USD | -58.439% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 90.954% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -2380.304% |
| SQZ Biotechnologies Company | -79.46 Million USD | 91.466% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -134.449% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 112.8% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 110.411% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -272.485% |
| Marizyme, Inc. | -65.34 Million USD | 89.623% |
| Genus plc | 7.9 Million USD | 185.838% |
| Pharming Group N.V. | -10.54 Million USD | 35.711% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -212.524% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -82.77% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 23.324% |
| ContraFect Corporation | -65.15 Million USD | 89.592% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -292.554% |
| IMV Inc. | -36.48 Million USD | 81.414% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 15.863% |
| ONE Bio Corp. | 8.67 Million USD | 178.155% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 86.882% |
| Mesoblast Limited | -87.95 Million USD | 92.29% |
| MultiCell Technologies, Inc. | -380.07 USD | -1784097.648% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -81.656% |
| Genscript Biotech Corporation | -95.47 Million USD | 92.898% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -972.284% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -184.82% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | -3.119% |
| Biomind Labs Inc. | -1.21 Million USD | -458.436% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -118.624% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 14.196% |
| Skye Bioscience, Inc. | -37.64 Million USD | 81.986% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -247.888% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 37.74% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -45180.449% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -38.787% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 2.888% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 57.274% |
| Accustem Sciences Inc. | -3.74 Million USD | -81.005% |
| EV Biologics, Inc. | -1.26 Million USD | -435.16% |
| Q BioMed Inc. | -2.05 Million USD | -230.453% |
| GB Sciences, Inc. | -1.36 Million USD | -398.004% |
| Alpha Cognition Inc. | -13.77 Million USD | 50.763% |
| CSL Limited | 2.64 Billion USD | 100.257% |
| Agentix Corp. | -1.37 Million USD | -393.461% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 88.646% |
| Enzolytics Inc. | -2.17 Million USD | -211.517% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Resverlogix Corp. | -3.61 Million USD | -87.845% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -113.821% |
| MetaStat, Inc. | - USD | Infinity% |
| Curative Biotechnology, Inc. | -5.81 Million USD | -16.57% |
| argenx SE | -295.05 Million USD | 97.702% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 89.167% |
| HST Global, Inc. | -146.21 Thousand USD | -4537.986% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 7019.592% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -286.444% |
| Halberd Corporation | -79.67 Thousand USD | -8410.969% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 197.929% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -124.088% |
| Zenith Capital Corp. | -10.59 Million USD | 36.002% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -70.682% |
| GeneThera, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -63.563% |
| AVAX Technologies, Inc. | -6.41 Million USD | -5.731% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -11119.609% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -238.195% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -29076.491% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | -4.76 Million USD | -42.188% |
| Helix BioMedix, Inc. | -1.05 Million USD | -542.124% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -77.565% |
| Kadimastem Ltd | -3.3 Million USD | -105.031% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| BioStem Technologies, Inc. | -8.48 Million USD | 20.061% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -1436.402% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -407.791% |
| LadRx Corporation | 400.44 Thousand USD | 1793.425% |
| Cell Source, Inc. | -5.32 Million USD | -27.437% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -1532.14% |
| Regen BioPharma, Inc. | 1.02 Million USD | 762.545% |
| Regen BioPharma, Inc. | 1.02 Million USD | 762.545% |
| Affymax, Inc. | -14.42 Million USD | 52.987% |
| Mobile Lads Corp. | -2.26 Million USD | -199.617% |
| Itoco Inc. | -1.86 Million USD | -262.826% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -52.643% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -306.303% |
| International Stem Cell Corporation | -131 Thousand USD | -5076.489% |
| CytoDyn Inc. | -49.84 Million USD | 86.394% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -8480.213% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -2872.555% |
| Qrons Inc. | -789.34 Thousand USD | -759.09% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -620.233% |
| SYBLEU INC | -180.3 Thousand USD | -3660.981% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.08 Million USD | -224.82% |
| Rebus Holdings, Inc. | -1.02 Million USD | -564.824% |
| GlobeImmune, Inc. | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -320.478% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -12394.841% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -168.005% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 85.894% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -220.776% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -768.397% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -114.053% |
| Neutra Corp. | -233.46 Thousand USD | -2804.59% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 66.58% |
| PureTech Health plc | -65.69 Million USD | 89.678% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 68.113% |
| IXICO plc | -1.17 Million USD | -475.654% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 31.689% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 88.13% |
| CSL Limited | 2.64 Billion USD | 100.257% |
| Cellectis S.A. | -103.17 Million USD | 93.427% |